SCHEMBL1773804

SCHEMBL1773804

O=S(=O)(Oc1ccccc1-c1cccc2cccnc12)C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 0.53
METAP1 P53582 3/20 0.53
SLC40A1 Q9NP59 5/20 0.49
PDE4A P27815 3/20 0.46
PDE4C Q08493 3/20 0.46
PDE4D Q08499 3/20 0.46
LMNA P02545 2/20 0.44
HDAC6 Q9UBN7 1/20 0.44
GLRA3 O75311 1/20 0.43
GLRB P48167 1/20 0.43
KDM4E B2RXH2 2/20 0.43
ALOX12 P18054 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
HSP90AA1 P07900 1/20 0.41
G6PD P11413 1/20 0.41
NFKBIA P25963 1/20 0.41
AGTR1 P30556 1/20 0.41
GLO1 Q04760 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28787393 0.94 METAP2 (0.48) METAP2METAP1SLC40A1PDE4APDE4C
SCHEMBL249779 0.87 METAP2 (0.64) METAP2METAP1SLC40A1PDE4APDE4C
SCHEMBL12578335 0.82 METAP2 (0.51) METAP2METAP1SLC40A1PDE4APDE4C
SCHEMBL1773802 0.81 ENPP1 (0.54) METAP2METAP1SLC40A1PDE4APDE4C
SCHEMBL7023211 0.81 DRD2 (0.42) KDM4EMAPTALDH1A1
SCHEMBL16926997 0.79 DRD2 (0.41) LMNAKDM4EMAPTRAB9APOLB
SCHEMBL27854709 0.78 CCR1 (0.47) METAP2METAP1SLC40A1PDE4APDE4C
SCHEMBL1773202 0.76 SLC22A12 (0.44) LMNAKDM4E
SCHEMBL28787391 0.76 ENPP1 (0.55) METAP2METAP1SLC40A1PDE4APDE4C
SCHEMBL16582721 0.76 ERN1 (0.51) METAP2METAP1SLC40A1PDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112103-A1 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112103-A1 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND EPOR, CBR1, CBR3 METAP2 1193/4885METAP1 1416/4885SLC40A1 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.